Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors

Cancer Gene Therapy

Volumn 7, Issue 9, 2000, Pages 1263-1269

  Iwadate, Yasuo ^a   Tagawa, Masatoshi ^b   Namba, Hiroki ^b   Oga, Masaru ^a   Kawamura, Kiyoko ^b   Tasaki, Kentaro ^b   Sakiyama, Shigeru ^b   Yamaura, Akira ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Brain tumor; Gene therapy; Immunotherapy; Interleukin 2; Subcutaneous vaccination

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CELL MIGRATION; CONTROLLED STUDY; GENE THERAPY; GLIOSARCOMA; IMMUNE RESPONSE; MACROPHAGE; MALE; MICROGLIA; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANIMALIA;

EID: 0033770982     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700223     Document Type: Article

References (27)

1. Immunization with interleukin-2 transfected melanoma cells: A phase I-II study in patients with metastatic melanoma
2. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2: A phase I study
3. The immune system and nervous system
4. Immunologically privileged sites
5. Malignant melanoma: Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysate
6. Systemic immunity against a murine colon tumor (CT-26) produced by immunization with syngeneic cells expressing a transfected viral gene product
7. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
8. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ
9. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma
10. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells
11. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion
12. + cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system
13. Treatment of glioma by engineered interleukin 4-secreting cells
14. Generation of cytotoxic immune response during the progression of a rat glioma
15. Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus
16. Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging
17. Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus-thymidine kinase gene and ganciclovir administration
18. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
19. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
20. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines
21. Experimental and clinical studies of cytokine gene-modified tumor cells
22. Immunotherapy of prostate cancer in the dunning rat model: Use of cytokine gene-modified tumor vaccines
23. In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors
24. Immune modulation within the brain: Recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-γ
25. Histopathological and blood-brain barrier changes in rats induced by intracerebral injection of human recombinant interleukin-2
26. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumor
27. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection